Are we underdosing acne patients with generic isotretinoin?

Misha M. Mutizwa, David M. Sheinbein

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

With Roche's withdrawl of Accutane from the U.S. market in 2009, isotretinoin has only been available in its generic form. Many clinicians fail to realize that for approval by the U.S. Food and Drug Administration, a generic medication must have a bioequivalence between 80 percent and 125 percent of that of the innovator product. This potential variability in bioavailability between branded and generic medications is important to keep in mind with isotretinoin, given the implications for achieving a sustained remission in acne patients.

Original languageEnglish
Number of pages1
JournalDermatology Online Journal
Volume19
Issue number1
StatePublished - Jan 1 2013

Fingerprint Dive into the research topics of 'Are we underdosing acne patients with generic isotretinoin?'. Together they form a unique fingerprint.

  • Cite this